Please assess the completion status of the following clinical trial:

Trial Title: Lot-to-lot Consistency of Sci-B-Vac™ in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Any gender~* Age 18-45 years~* Healthy, as determined by a physical examination and values of laboratory tests~* If female, either is not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), is of childbearing potential and must agree to use an adequate birth control method~* Able and willing to give informed consent~Exclusion Criteria:~* Previous vaccination with any Hep B vaccine (HBV) (licensed or experimental)~* Treatment by immunosuppressant within 30 days of enrollment~* History of immunological function impairment~* Pregnancy or breastfeeding~* Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment~* Immunization with inactivated vaccines (e.g. influenza) within 2 week prior to enrolment~* Has received blood products or immunoglobulin within 90 days of enrollment or is likely to require blood products during the study period~* Subject in another clinical trial with an investigational drug or a biologic within 30 days of enrollment~* Has received granulocyte-macrophage colony stimulating factor (G/GM-CSF) or erythropoietin (EPO) within 30 days of enrollment or likely to require GM-CSF or erythropoietin during the study period~* Any history of cancer requiring chemotherapy or radiation within 5 years of randomization or current disease.~* Any skin abnormality or tattoo that would limit post-vaccination injection site assessment~* History of allergic reactions or anaphylactic reaction to any vaccine component~* Unwilling, or unable in the opinion of the investigator, to comply with study requirements~* Immediate family members of study center staff~* Current or past hepatitis B infection or prior vaccination as evidenced by HBV markers~* Known hepatitis C infection or positive Hepatitis C serology at screening, unless treated and cured~* Known human immunodeficiency virus (HIV) infection or positive HIV serology at screening~* Renal impairment with Glomerular Filtration Rate (GFR) \<90 mL/min/ 1.73 m2 at screening~* BMI ≥ 35~* Uncontrolled hypertension~* Diagnosis of Type 1 or Type 2 diabetes or HbA1C ≥ 6.5% at screening~* Any laboratory test abnormality that would be considered of Grade 1 severity or above as per FDA guidelines for grading clinical laboratory abnormalities and is considered as clinically significant by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sci-B-Vac Lot A Hep B Vaccination (Type: EXPERIMENTAL): Sci-B-Vac Lot A Hepatitis B Vaccination
- Sci-B-Vac Lot B Hep B Vaccination (Type: EXPERIMENTAL): Sci-B-Vac Lot B Hepatitis B Vaccination
- Sci-B-Vac Lot C Hep B Vaccination (Type: EXPERIMENTAL): Sci-B-Vac Lot C Hepatitis B Vaccination
- Comparator: ENGERIX-B Hep B Vaccination (Type: ACTIVE_COMPARATOR): Active Comparator: ENGERIX-B Hepatitis B Vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete